The two pharmaceutical companies are facing a legal battle after Mylan filed a new drug application for a generic of Novo Nordisk’s Victoza.
List view / Grid view
Filter the results
Sterility assurance for a pharmaceutical product is critical, and includes many aspects outside of the actual sterilization cycle or aseptic process.
New research has found that of the 38 warning letters handed out by the FDA in 2019, the US and India received the vast majority.
Drug companies are still raising prices for brand-name prescription medicines but not as often or by as much as they used to.
A warning letter has been sent to Emcure Pharmaceuticals after an FDA facility inspection found that the company did not adequately investigate sterility failures.
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this second piece, we discuss the challenges, legal implications and perceptions of cannabinoids.
The FDA has given its approval to RINVOQ for the treatment of active rheumatoid arthritis after the drug reached its endpoints in clinical trials.
The worldwide trade of the cephalosporin class of antibiotics will increase to $14.1 billion by the end of 2025.
A leaked government dossier has stated that in the event of a no-deal Brexit, the UK will face severe medicinal shortages.
An MHRA consultation is due to end on 31 August, with public comments on AQbD principles closing soon.
This series investigates the growing interest from the pharmaceutical industry in cannabinoids. In this first piece, we hear from industry experts about the current situation of the ingredient on the pharmaceutical market.
An open letter has underscored the challenges of return failure in the US drug supply chain, especially after the introduction of the Drug Supply Chain Security Act in November.
Researchers use the Earth’s biodiversity for pharmaceuticals, but this is under threat due to climate change and habitat destruction. The Nagoya Protocol aims to conserve these resources in a sustainable way.
The global alopecia treatment market is projected to exhibit a CAGR of 4.9 percent from 2018–2026.